Related Experiment Videos
Thyroxine suppressive therapy in patients with nodular thyroid disease
1Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Annals of Internal Medicine
|March 7, 1998
Summary
Thyroid nodules rarely shrink with thyroxine suppressive therapy. Most benign nodules remain stable, and monitoring is preferred over treatment to avoid side effects like osteoporosis and heart disease.
Area of Science:
- Endocrinology
- Oncology
- Internal Medicine
Background:
- Thyroid nodules are common, and their management involves assessing clinical significance and natural history.
- Thyroxine suppressive therapy is sometimes used, but its efficacy and safety require careful evaluation.
Purpose of the Study:
- To review evidence on thyroxine suppressive therapy for thyroid nodules.
- To assess the clinical importance, natural history, effects, and side effects of this therapy.
Main Methods:
- Systematic review of English-language articles (1986-1996) from MEDLINE and other sources.
- Included randomized and nonrandomized trials of thyroxine suppressive therapy for thyroid nodules.
- Nodule evaluation primarily used fine-needle aspiration biopsy and ultrasonography.
Main Results:
- Thyroxine therapy shows limited efficacy, shrinking only 10-20% of thyroid nodules.
- Fine-needle aspiration biopsy is reliable for distinguishing benign from malignant nodules.
- Spontaneous nodule shrinkage occurs, and thyroxine therapy does not prevent new nodule formation or growth.
- Postoperative thyroxine may not prevent recurrence, except in patients with prior radiation therapy.
- Long-term suppressive therapy carries risks, including osteoporosis and heart disease.
Conclusions:
- Observation without thyroxine treatment is recommended for cytologically benign thyroid nodules.
- Most benign nodules remain stable and benign over time.
- Increased nodule size warrants repeat biopsy or surgical intervention.